SAN DIEGO, CA, Oct. 04, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Medical marijuana, Inc. (OTC: MJNA) (the “Company”), the first publicly traded cannabis company in the United States that launched the first cannabis-derived products, brands, and supply chain, today announced that it has entered into an asset purchase agreement with MFINITY Global LLC, a direct selling organization focused on On promoting natural health and a rewarding sales model. In addition, Bill Andreoli, President of MFINITY Global, will become President of Medical Marijuana, Inc. Subsidiary, Kannaway, LLC.
The MFINITY product line contains Muscadine, a powerful antioxidant that provides many health benefits. MFINITY products will be marketed and sold exclusively under the Kannaway brand and are now available for sale through independent Kannaway distributors and on Kannaway.com. MFINITY’s sales team, known as Brand Ambassadors, will become Kannaway’s Brand Ambassadors and will immediately have access to market and sell the world’s leading non-psychoactive and cannabis products.
The asset purchase is consistent with Medical Marijuana Inc.’s newly implemented growth model. To expand through acquisition. The addition of newly appointed Kannaway President, Bill Andreoli, leads to more positions for the company to pursue this strategy due to Mr. Andreoli’s successful completion of more than a dozen acquisitions throughout his career. Medical Marijuana’s in-house manufacturing and distribution capabilities enable the company to easily add formulations and product lines from acquired companies and drive product sales through its international platform and global footprint spanning four continents. Medical Marijuana, Inc. To grow through this acquisition strategy.
“I couldn’t be more excited to assume my new role as President of Kannaway and lead the company and its expansion strategy,” said Bill Andreoli, newly appointed Kannaway President. “Successfully acquiring and integrating brands is something I have done with great success in the past and I look forward to implementing that model here at Medical Marijuana, Inc.”
“This agreement puts Kannaway on an exciting new path, in addition to the acquisition,” said Blake Schroeder, CEO of Medical Marijuana, Inc.. For the future. We are also excited to add the MFINITY product line to our portfolio and welcome the MFINITY Brand Ambassador team to Kannaway because we believe both will enhance our value.”
About Medical Marijuana, Inc.:
We are Firsts®. Medical marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabis space: a global group of hemp-based nutritional brands led by Kanawee® And HempMeds®; leader in sourcing high quality, legal, non-psychoactive cannabis products derived from industrial hemp; and the cannabis-based clinical research and plant-based drug development segment led by pharmaceutical investment firms and their partners incl AXIM® Biotechnologies, Inc. And Neurobatics. Medical Marijuana, Inc. As the best CBD product by CNBC. Medical Marijuana, Inc. Also the first company to obtain historical import authorizations for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in the development of international markets. The company’s main product Real scientific hemp oil It has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc. is headquartered in In San Diego, California, additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. Watch the Medical Marijuana, Inc. video. , click here.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, and is subject to the safe harbor laws established by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and are subject to risks and uncertainties. These forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ. materially from the data presented here.
Disclosure from the Food and Drug Administration (FDA):
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that violate the US Controlled Substances Act.
Investor Relations Contact:
P. (858) 283-4016